-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
The 16th New Product of the Year: Agaritaband Injection Approved by Shijiazhuang Sihua Pharmaceutical Group
Category:
发布时间：2023-03-25
【概要描述】
On March 25, it was learned that Shijiazhuang Sihua Pharmaceutical Group’s Class 4 chemical drug application for Argatroban Injection (2 mL: 10 mg) has been granted a Drug Registration Certificate by the National Medical Products Administration and is deemed to have passed the Consistency Evaluation. This marks the group’s 16th new product approved this year, signaling a strong start to the first quarter in terms of R&D innovation.
On March 25, it was learned that Shijiazhuang Sihua Pharmaceutical Group’s Class 4 chemical drug application for Argatroban Injection (2 mL: 10 mg) has been granted a Drug Registration Certificate by the National Medical Products Administration and is deemed to have passed the Consistency Evaluation. This marks the group’s 16th new product approved this year, signaling a strong start to the first quarter in terms of R&D innovation.
According to reports, argatroban injection is a thrombin inhibitor and can be used for the acute-phase treatment of ischemic stroke within 48 hours of onset.
To date, Shijiazhuang Sihua Pharmaceutical Group has achieved consistency evaluation—or is deemed to have achieved such evaluation—for a total of 43 drug varieties encompassing 55 dosage forms and strengths.
In recent years, Shijiazhuang Sihua Pharmaceutical Group has been driven by innovation, actively implementing a “API-plus-formulation” development strategy. The company has aligned its innovation chain with the industrial value chain, comprehensively advancing the research and development of high-end, complex generic drugs, innovative medicines, specialty APIs, and products undergoing bioequivalence evaluation. It is also accelerating its strategic positioning in key therapeutic areas such as antiviral, antibacterial, cough-and-phlegm-relieving, anti-tumor, central nervous system, cardiovascular, gastrointestinal, and anesthetic therapies.
Leveraging a comprehensive package of business-friendly policies at the national, provincial, and municipal levels, the group has adopted an innovation mechanism that integrates industry, academia, research, and application, establishing an innovation consortium led by the enterprise, supported by universities and research institutes, and characterized by close collaboration among all relevant innovation players. This initiative continuously empowers the enterprise to enter new growth areas, build new competitive advantages, forge a new development paradigm, generate new momentum, and create new opportunities.
Continuous innovation has enabled Shijiazhuang Sihua Pharmaceutical to establish a new paradigm of product iteration and development—“developing a batch, stockpiling a batch, and commercializing a batch.” Its R&D achievements have accumulated steadily and are now being translated into tangible results, with its R&D efficiency in specialty generic drugs and the number of applications filed ranking among the top in the domestic industry. Currently, the company has nearly 200 projects in development and more than 100 new products awaiting approval. This ever-expanding portfolio of innovative outcomes provides a stronger foundation and a powerful growth engine for the company’s high-quality development, helping it move up the value chain toward the mid- to high-end segments of the industry.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091